Hennion & Walsh Asset Management Inc. Acquires 61,467 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Hennion & Walsh Asset Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 19.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 371,583 shares of the company's stock after purchasing an additional 61,467 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Teva Pharmaceutical Industries were worth $8,190,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC boosted its position in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company's stock worth $621,337,000 after buying an additional 2,204,623 shares during the last quarter. State Street Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after buying an additional 1,778,268 shares during the period. Geode Capital Management LLC grew its stake in Teva Pharmaceutical Industries by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company's stock valued at $157,571,000 after buying an additional 291,124 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock worth $86,350,000 after acquiring an additional 4,732,374 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Finally, Barclays upped their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $20.88.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $0.27 during trading on Thursday, hitting $21.68. 7,199,934 shares of the stock were exchanged, compared to its average volume of 9,598,934. Teva Pharmaceutical Industries Limited has a 1-year low of $10.83 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a market capitalization of $24.56 billion, a price-to-earnings ratio of -25.50, a price-to-earnings-growth ratio of 1.06 and a beta of 0.73. The company's fifty day simple moving average is $19.06 and its 200-day simple moving average is $18.14.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company's stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company's stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.